Lymecycline is a tetracycline-class antibiotic used primarily for the treatment of acne vulgaris and other susceptible bacterial infections. It is a semi-synthetic derivative of tetracycline and is formulated as a stable pharmaceutical compound suitable for oral administration.
Lymecycline exhibits antibacterial activity by inhibiting bacterial protein synthesis. It enters susceptible bacterial cells and binds to the 30S ribosomal subunit, interfering with the attachment of aminoacyl-tRNA and thereby preventing the addition of amino acids to growing bacterial proteins.
Lymecycline is a tetracycline derivative with the molecular formula C29H38N4O10 and a molecular weight of approximately 634.64 g/mol. Its CAS Number is 992-21-0.
Lymecycline is supplied as a pharmaceutical active ingredient and is particularly associated with oral formulations for dermatological applications.
Lymecycline acts primarily by inhibiting bacterial protein synthesis. The tetracycline component binds reversibly to the 30S bacterial ribosomal subunit, preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
This inhibits bacterial protein synthesis and suppresses the growth of susceptible microorganisms.
Lymecycline is most commonly used in pharmaceutical formulations for the treatment of moderate to severe acne vulgaris. Its antibacterial and anti-inflammatory properties make it useful in dermatological therapy.
It may also have activity against susceptible organisms associated with other bacterial infections, although specific clinical uses depend on applicable regulatory approvals and prescribing information.
Lymecycline API can be evaluated using validated analytical procedures for identification, assay, related substances, water content, residual solvents, elemental impurities and other applicable quality attributes.
Chromatographic and spectroscopic techniques may be used for identity, assay and purity determination. Appropriate controls should be established for tetracycline-related impurities, degradation products and other process-related impurities.
Acceptance criteria should be based on the applicable manufacturer's drug-substance specification, Certificate of Analysis and relevant pharmacopoeial and regulatory requirements.
Lymecycline should be stored in a tightly closed pharmaceutical-grade container under controlled conditions. It should be protected from excessive heat, moisture and direct light.
Specific storage and transportation requirements should follow the applicable manufacturer's approved specification.
Lymecycline API may be supplied for qualified pharmaceutical manufacturing, formulation development, analytical and research applications, subject to applicable quality and regulatory requirements.
Lymecycline API is available for qualified pharmaceutical development and manufacturing requirements subject to applicable quality and regulatory standards. Customers can request product specifications, Certificate of Analysis, analytical documentation, packaging information and commercial details according to their requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 95.0–105.0% |
| Loss on Drying | NMT 5.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0–4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |